Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over)

Document first published:
Page updated:
Publication type:

Baricitinib is recommended to be available as a treatment option through routine commissioning for adults and children 2 years and over with monogenic interferonopathies within the criteria set out in this document.